newsfilter
← Latest News
GlobeNewswire·

GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

  • GRI Bio, Inc. (NASDAQ: GRI) will participate in the Webull Financial Corporate Connect Webinar Series on February 10-11, 2026.
  • The company's live presentation is scheduled for Wednesday, February 11, 2026, at 1:00 PM EST.
  • Marc Hertz, PhD, President, Chief Executive Officer, and Director, will present during the session.
  • GRI Bio is a clinical-stage biopharmaceutical company developing immune cell modulators for inflammatory, fibrotic, and autoimmune diseases.
  • The company's lead program, GRI-0621, is an oral RARβγ agonist targeting iNKT cells for the treatment of idiopathic pulmonary fibrosis.
  • GRI Bio is also developing type 2 diverse NKT agonists for systemic lupus erythematosus.
  • The company maintains a library of over 500 proprietary compounds to support its pipeline growth.
  • The press release includes forward-looking statements regarding development timelines, regulatory approvals, and financial performance.
  • Actual results may differ from projections due to risks including regulatory challenges, financing needs, and clinical trial outcomes.
  • Investor inquiries can be directed to Jenene Thomas at JTC Team, LLC via phone or email.